This article first appeared on GuruFocus.
ETF flows into Amgen (AMGN) extended a three-day buying streak on Tuesday, Nov. 10, with a net $66.8 million added by funds. Forty-five ETFs bought shares while 15 sold. The run follows net inflows of $103.1 million on Nov. 9 and $60.6 million on Nov. 6, after a net outflow of $79.8 million on Nov. 5. ETF activity has favored the stock across four of the past five sessions.
For the full record of ETF and guru buying and selling in AMGN, see the AMGN guru trades page.
Which ETFs bought AMGN on Tuesday?
The largest buyers by dollar value were QQQ ($35.4 million), SPY ($8.0 million) and XLV ($4.9 million). In all, 45 ETFs added shares and 15 cut them.
QQQ led the move with a $35.4 million increase, adding 76,102 shares for a 0.67% stake change and a 1.16% portfolio weight. SPY added $8.0 million and XLV $4.9 million, with XLV holding the largest weight at 3.68%. QQQM ($2.9 million), RSP ($1.7 million) and HDV ($1.5 million) also added, alongside QLD and TQQQ. Amgen operates in the Healthcare sector, in the Drug Manufacturers – General industry, with a market cap of $253.2 billion.
Have ETFs been buying or selling AMGN lately?
Over the last 5 reported days, ETFs were net buyers on 4 and net sellers on 1, so the recent trend is mostly buying.
What does AMGN do?
Amgen is one of the world’s largest biotechnology companies, discovering, developing, and manufacturing biologic and small-molecule therapies.
Amgen’s trailing-12-month revenue was $38.98 billion, up 8.1% over one year, with a gross margin of 74.0% and a net margin of 24.1%. It trades at a P/E of 27.15, P/B of 17.64 and P/S of 6.54, with a market cap of $253.2 billion. The GF Score is 85 and GF Value is $373.10 versus a price of $468.11. The dividend yield is 2.23% and the year-to-date return is 45.94%.
AMGN at a glance
Compare AMGN’s share price with its GF Value, see recent insider trades, or check which gurus own AMGN.